| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 39 | 2022 | 3970 | 3.590 |
Why?
|
| Testicular Neoplasms | 13 | 2022 | 751 | 2.840 |
Why?
|
| Carcinoma, Renal Cell | 30 | 2022 | 2910 | 2.790 |
Why?
|
| Fallopian Tube Neoplasms | 15 | 2022 | 349 | 2.350 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 9 | 2022 | 475 | 2.090 |
Why?
|
| Immunohistochemistry | 51 | 2022 | 11790 | 1.830 |
Why?
|
| Teratoma | 7 | 2022 | 385 | 1.830 |
Why?
|
| Ovarian Neoplasms | 31 | 2022 | 4712 | 1.820 |
Why?
|
| Cystadenocarcinoma, Serous | 19 | 2018 | 457 | 1.770 |
Why?
|
| Leiomyomatosis | 2 | 2022 | 70 | 1.700 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 3 | 2020 | 69 | 1.520 |
Why?
|
| Genital Neoplasms, Female | 5 | 2021 | 510 | 1.340 |
Why?
|
| Paired Box Transcription Factors | 5 | 2013 | 218 | 1.330 |
Why?
|
| Prostatic Neoplasms | 24 | 2022 | 10525 | 1.200 |
Why?
|
| Kidney Medulla | 3 | 2021 | 191 | 1.140 |
Why?
|
| Uterine Neoplasms | 5 | 2022 | 1473 | 1.130 |
Why?
|
| Urinary Bladder Neoplasms | 11 | 2022 | 2029 | 1.120 |
Why?
|
| SOXD Transcription Factors | 2 | 2022 | 50 | 1.120 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2022 | 53 | 1.110 |
Why?
|
| GATA3 Transcription Factor | 2 | 2015 | 163 | 1.080 |
Why?
|
| Adenocarcinoma | 14 | 2022 | 6338 | 1.070 |
Why?
|
| Carcinoma | 8 | 2022 | 2307 | 1.050 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 3 | 2022 | 191 | 1.050 |
Why?
|
| Metaplasia | 3 | 2021 | 314 | 1.000 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 2 | 2021 | 40 | 0.990 |
Why?
|
| Antigens, Neoplasm | 3 | 2020 | 2003 | 0.940 |
Why?
|
| Peritoneal Neoplasms | 4 | 2022 | 599 | 0.930 |
Why?
|
| Adenomatoid Tumor | 1 | 2022 | 11 | 0.920 |
Why?
|
| Smooth Muscle Tumor | 2 | 2020 | 66 | 0.880 |
Why?
|
| Catenins | 1 | 2021 | 41 | 0.880 |
Why?
|
| Epithelioid Cells | 1 | 2022 | 74 | 0.870 |
Why?
|
| Seminal Vesicles | 1 | 2021 | 107 | 0.860 |
Why?
|
| Diagnosis, Differential | 25 | 2022 | 13274 | 0.860 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2021 | 485 | 0.830 |
Why?
|
| Chromosomes, Human, X | 4 | 2015 | 310 | 0.830 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2020 | 85 | 0.820 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 5 | 2022 | 325 | 0.790 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2021 | 565 | 0.780 |
Why?
|
| Cervical Intraepithelial Neoplasia | 3 | 2013 | 315 | 0.780 |
Why?
|
| Carcinoma, Papillary | 3 | 2021 | 798 | 0.740 |
Why?
|
| Urothelium | 1 | 2021 | 285 | 0.730 |
Why?
|
| Stathmin | 3 | 2015 | 59 | 0.730 |
Why?
|
| Endometrial Neoplasms | 6 | 2015 | 1333 | 0.680 |
Why?
|
| Urethra | 1 | 2020 | 407 | 0.680 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 58 | 0.680 |
Why?
|
| Sarcoma | 4 | 2022 | 1854 | 0.670 |
Why?
|
| Plasma Cells | 1 | 2021 | 591 | 0.660 |
Why?
|
| Translocation, Genetic | 6 | 2015 | 1425 | 0.650 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2015 | 1962 | 0.640 |
Why?
|
| Wolffian Ducts | 2 | 2018 | 27 | 0.630 |
Why?
|
| Precancerous Conditions | 5 | 2021 | 964 | 0.610 |
Why?
|
| Fumarate Hydratase | 3 | 2022 | 43 | 0.600 |
Why?
|
| Angiomyolipoma | 1 | 2017 | 191 | 0.590 |
Why?
|
| Carcinoma in Situ | 6 | 2022 | 821 | 0.590 |
Why?
|
| Male Urogenital Diseases | 1 | 2015 | 50 | 0.580 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2015 | 23 | 0.570 |
Why?
|
| Female Urogenital Diseases | 1 | 2015 | 52 | 0.570 |
Why?
|
| Terminology as Topic | 4 | 2021 | 1620 | 0.570 |
Why?
|
| Predictive Value of Tests | 18 | 2022 | 15252 | 0.560 |
Why?
|
| Urinary Bladder | 2 | 2020 | 1125 | 0.540 |
Why?
|
| Oncogenes | 3 | 2020 | 1244 | 0.530 |
Why?
|
| Prostate | 9 | 2022 | 1564 | 0.530 |
Why?
|
| Adenoma | 3 | 2021 | 2130 | 0.520 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2021 | 2668 | 0.520 |
Why?
|
| Radiotherapy | 1 | 2021 | 1623 | 0.500 |
Why?
|
| Trophoblasts | 1 | 2015 | 219 | 0.500 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2014 | 287 | 0.490 |
Why?
|
| Humans | 149 | 2022 | 708843 | 0.470 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 3773 | 0.460 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 726 | 0.460 |
Why?
|
| Carcinoma, Medullary | 2 | 2017 | 124 | 0.410 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 296 | 0.390 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2022 | 768 | 0.390 |
Why?
|
| Female | 89 | 2022 | 375205 | 0.390 |
Why?
|
| Prostatectomy | 8 | 2022 | 1800 | 0.380 |
Why?
|
| Repressor Proteins | 1 | 2021 | 3075 | 0.380 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2022 | 319 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 418 | 0.360 |
Why?
|
| Male | 74 | 2022 | 349524 | 0.350 |
Why?
|
| Vulvar Neoplasms | 2 | 2008 | 277 | 0.340 |
Why?
|
| Paget Disease, Extramammary | 1 | 2008 | 40 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2022 | 8638 | 0.330 |
Why?
|
| Fallopian Tubes | 4 | 2017 | 171 | 0.330 |
Why?
|
| Pathology | 2 | 2021 | 273 | 0.330 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2022 | 2971 | 0.320 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 5266 | 0.310 |
Why?
|
| Pyrroles | 2 | 2010 | 1182 | 0.290 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 917 | 0.290 |
Why?
|
| Biopsy | 11 | 2021 | 6766 | 0.290 |
Why?
|
| Kidney Tubules, Collecting | 2 | 2018 | 180 | 0.290 |
Why?
|
| Aged | 51 | 2022 | 161488 | 0.280 |
Why?
|
| Mutation | 20 | 2022 | 29262 | 0.280 |
Why?
|
| Pleural Neoplasms | 1 | 2010 | 600 | 0.270 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2016 | 507 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2020 | 3876 | 0.270 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 2245 | 0.270 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2017 | 134 | 0.270 |
Why?
|
| Hysterectomy | 2 | 2010 | 902 | 0.270 |
Why?
|
| Cell Proliferation | 11 | 2022 | 10803 | 0.260 |
Why?
|
| Indoles | 2 | 2010 | 1857 | 0.260 |
Why?
|
| Antineoplastic Agents | 6 | 2015 | 13714 | 0.260 |
Why?
|
| Mesothelioma | 1 | 2010 | 774 | 0.260 |
Why?
|
| Lymph Nodes | 2 | 2015 | 3409 | 0.260 |
Why?
|
| Pelvic Neoplasms | 3 | 2013 | 246 | 0.260 |
Why?
|
| Blood Vessels | 1 | 2010 | 1165 | 0.250 |
Why?
|
| Middle Aged | 53 | 2022 | 213752 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 2 | 2008 | 985 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7487 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2008 | 327 | 0.240 |
Why?
|
| Malacoplakia | 1 | 2022 | 16 | 0.240 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2022 | 220 | 0.240 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2022 | 24 | 0.230 |
Why?
|
| beta Catenin | 2 | 2021 | 1053 | 0.230 |
Why?
|
| Blotting, Western | 4 | 2015 | 5456 | 0.230 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2022 | 25 | 0.230 |
Why?
|
| Sertoli Cell Tumor | 1 | 2022 | 25 | 0.230 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2022 | 438 | 0.220 |
Why?
|
| Spermatogonia | 1 | 2021 | 35 | 0.220 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2022 | 170 | 0.220 |
Why?
|
| Leydig Cell Tumor | 1 | 2021 | 26 | 0.220 |
Why?
|
| Granular Cell Tumor | 1 | 2021 | 52 | 0.220 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2022 | 88 | 0.220 |
Why?
|
| DNA Mutational Analysis | 6 | 2018 | 4317 | 0.210 |
Why?
|
| Adult | 39 | 2022 | 211041 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2002 | 389 | 0.210 |
Why?
|
| Granulosa Cell Tumor | 1 | 2021 | 61 | 0.210 |
Why?
|
| Vulvar Diseases | 1 | 2021 | 59 | 0.210 |
Why?
|
| Artifacts | 1 | 2010 | 1904 | 0.210 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2014 | 3006 | 0.210 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2020 | 39 | 0.210 |
Why?
|
| Genes, BRCA2 | 4 | 2013 | 590 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2010 | 622 | 0.210 |
Why?
|
| MART-1 Antigen | 1 | 2020 | 78 | 0.210 |
Why?
|
| Seminoma | 1 | 2021 | 111 | 0.200 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 1667 | 0.200 |
Why?
|
| Genes, BRCA1 | 4 | 2013 | 761 | 0.200 |
Why?
|
| Laryngeal Neoplasms | 1 | 2004 | 490 | 0.200 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2020 | 41 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 8877 | 0.200 |
Why?
|
| Uterine Cervical Diseases | 1 | 2020 | 78 | 0.200 |
Why?
|
| Receptors, Somatostatin | 1 | 2020 | 125 | 0.190 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 87 | 0.190 |
Why?
|
| Carcinoma, Ductal | 1 | 2020 | 106 | 0.190 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 265 | 0.190 |
Why?
|
| Vaginal Diseases | 1 | 2020 | 96 | 0.190 |
Why?
|
| Aged, 80 and over | 19 | 2022 | 58184 | 0.190 |
Why?
|
| Cell Differentiation | 5 | 2021 | 11718 | 0.180 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 210 | 0.180 |
Why?
|
| Urology | 2 | 2020 | 368 | 0.180 |
Why?
|
| Cell Nucleus | 3 | 2021 | 3021 | 0.180 |
Why?
|
| Smad4 Protein | 1 | 2019 | 169 | 0.180 |
Why?
|
| Succinate Dehydrogenase | 2 | 2021 | 159 | 0.180 |
Why?
|
| Choristoma | 1 | 2020 | 216 | 0.180 |
Why?
|
| Kallikreins | 1 | 2020 | 267 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 3708 | 0.170 |
Why?
|
| Tissue Array Analysis | 4 | 2016 | 580 | 0.170 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 11126 | 0.170 |
Why?
|
| Testis | 1 | 2021 | 813 | 0.160 |
Why?
|
| Gadolinium DTPA | 3 | 2017 | 827 | 0.160 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 32 | 0.160 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 220 | 0.160 |
Why?
|
| 5-Methylcytosine | 1 | 2017 | 159 | 0.160 |
Why?
|
| Thyroid Gland | 1 | 2004 | 1173 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2022 | 2895 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 641 | 0.150 |
Why?
|
| Gene Expression Profiling | 8 | 2021 | 9556 | 0.150 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 19423 | 0.150 |
Why?
|
| Saposins | 1 | 2016 | 17 | 0.150 |
Why?
|
| Sarcoidosis | 1 | 2022 | 520 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 534 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 6 | 2021 | 3693 | 0.150 |
Why?
|
| Ki-67 Antigen | 3 | 2015 | 629 | 0.150 |
Why?
|
| Gene Amplification | 4 | 2014 | 1087 | 0.150 |
Why?
|
| Cadherins | 1 | 2021 | 921 | 0.150 |
Why?
|
| Retrospective Studies | 16 | 2021 | 71483 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2022 | 1597 | 0.150 |
Why?
|
| Mesonephroma | 1 | 2015 | 19 | 0.150 |
Why?
|
| Northern Ireland | 1 | 2015 | 39 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 2561 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 2189 | 0.140 |
Why?
|
| Histone Code | 1 | 2016 | 161 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 94 | 0.140 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 1202 | 0.140 |
Why?
|
| Specialization | 1 | 2020 | 791 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2019 | 991 | 0.140 |
Why?
|
| Disease Progression | 6 | 2020 | 13298 | 0.130 |
Why?
|
| Papillomavirus Infections | 2 | 2020 | 1470 | 0.130 |
Why?
|
| Germ Cells | 1 | 2018 | 588 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2021 | 626 | 0.130 |
Why?
|
| Thrombospondin 1 | 1 | 2016 | 252 | 0.130 |
Why?
|
| Keratin-7 | 2 | 2017 | 47 | 0.130 |
Why?
|
| S100 Proteins | 1 | 2015 | 259 | 0.130 |
Why?
|
| Urogenital Neoplasms | 1 | 2015 | 140 | 0.130 |
Why?
|
| Karyotyping | 2 | 2009 | 1269 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11253 | 0.130 |
Why?
|
| Ubiquitination | 1 | 2018 | 998 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 114 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2022 | 34151 | 0.130 |
Why?
|
| Meningioma | 1 | 2022 | 1203 | 0.120 |
Why?
|
| Leuprolide | 1 | 2015 | 309 | 0.120 |
Why?
|
| Peptides, Cyclic | 1 | 2016 | 411 | 0.120 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 6497 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 1922 | 0.120 |
Why?
|
| Health Resources | 1 | 2020 | 922 | 0.120 |
Why?
|
| Cyclin E | 1 | 2013 | 165 | 0.120 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2016 | 243 | 0.120 |
Why?
|
| Ovary | 1 | 2018 | 997 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2022 | 1221 | 0.120 |
Why?
|
| Calcinosis | 1 | 2022 | 1435 | 0.120 |
Why?
|
| Observer Variation | 5 | 2021 | 2687 | 0.120 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2012 | 20 | 0.120 |
Why?
|
| Prognosis | 12 | 2019 | 28919 | 0.120 |
Why?
|
| Young Adult | 13 | 2022 | 55940 | 0.120 |
Why?
|
| Protective Agents | 1 | 2014 | 164 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 681 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2013 | 168 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 1335 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 9584 | 0.110 |
Why?
|
| Racemases and Epimerases | 2 | 2021 | 131 | 0.110 |
Why?
|
| Cell Lineage | 2 | 2018 | 2630 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14836 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2017 | 1812 | 0.110 |
Why?
|
| Protein Kinase C | 1 | 2017 | 1292 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2021 | 4169 | 0.110 |
Why?
|
| Gene Order | 1 | 2011 | 188 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 1214 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 3 | 2010 | 1853 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 637 | 0.100 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 2987 | 0.100 |
Why?
|
| Pelvis | 1 | 2015 | 685 | 0.100 |
Why?
|
| Intestines | 1 | 2020 | 1929 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 1449 | 0.100 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2010 | 23 | 0.100 |
Why?
|
| Melanoma | 2 | 2008 | 5194 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 4254 | 0.100 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2951 | 0.100 |
Why?
|
| Adenoma, Islet Cell | 1 | 2010 | 84 | 0.100 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 16959 | 0.100 |
Why?
|
| Appendectomy | 1 | 2013 | 382 | 0.100 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2010 | 76 | 0.100 |
Why?
|
| Elafin | 1 | 2010 | 29 | 0.100 |
Why?
|
| Risk Assessment | 7 | 2021 | 23284 | 0.100 |
Why?
|
| Phenotype | 8 | 2022 | 16306 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 1392 | 0.100 |
Why?
|
| Biopsy, Needle | 3 | 2021 | 1682 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2020 | 1889 | 0.100 |
Why?
|
| Epithelial Cells | 2 | 2020 | 3690 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 524 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5197 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 5982 | 0.100 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1060 | 0.090 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 759 | 0.090 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1378 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 1860 | 0.090 |
Why?
|
| Cystectomy | 1 | 2014 | 628 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2014 | 2936 | 0.090 |
Why?
|
| Keratin-19 | 1 | 2008 | 32 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 908 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2021 | 3776 | 0.090 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 148 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 1814 | 0.090 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 337 | 0.090 |
Why?
|
| Hernia, Ventral | 1 | 2010 | 136 | 0.090 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2010 | 260 | 0.090 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 5112 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2010 | 1449 | 0.090 |
Why?
|
| Laparoscopy | 2 | 2010 | 1981 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2010 | 241 | 0.090 |
Why?
|
| Histones | 1 | 2018 | 2579 | 0.090 |
Why?
|
| Watchful Waiting | 1 | 2012 | 451 | 0.090 |
Why?
|
| Ascites | 1 | 2010 | 343 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 605 | 0.090 |
Why?
|
| Vulva | 1 | 2008 | 84 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6765 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2017 | 2641 | 0.080 |
Why?
|
| SEER Program | 1 | 2013 | 1549 | 0.080 |
Why?
|
| Treatment Outcome | 12 | 2020 | 61932 | 0.080 |
Why?
|
| Child | 10 | 2022 | 73636 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2021 | 12005 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2017 | 2333 | 0.080 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2009 | 291 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 4930 | 0.080 |
Why?
|
| Nephrectomy | 4 | 2017 | 993 | 0.080 |
Why?
|
| Genes, p53 | 4 | 2013 | 764 | 0.080 |
Why?
|
| Health Care Surveys | 3 | 2021 | 2502 | 0.080 |
Why?
|
| Chromatin | 1 | 2018 | 2693 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2013 | 1421 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3464 | 0.080 |
Why?
|
| Sex Factors | 1 | 2021 | 10566 | 0.080 |
Why?
|
| Vaginal Neoplasms | 1 | 2007 | 106 | 0.080 |
Why?
|
| Boston | 3 | 2015 | 9402 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2021 | 17218 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2017 | 1897 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 3026 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2878 | 0.080 |
Why?
|
| Cervix Uteri | 1 | 2010 | 575 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2022 | 7763 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2013 | 3701 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 980 | 0.070 |
Why?
|
| Nevus, Pigmented | 1 | 2008 | 215 | 0.070 |
Why?
|
| Risk Factors | 8 | 2021 | 69553 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2016 | 13314 | 0.070 |
Why?
|
| Time Factors | 6 | 2020 | 41038 | 0.070 |
Why?
|
| Microtubules | 1 | 2011 | 1206 | 0.070 |
Why?
|
| Corpus Luteum | 1 | 2004 | 91 | 0.070 |
Why?
|
| Organ Size | 1 | 2010 | 2317 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2004 | 79 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 20308 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 1108 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2021 | 10507 | 0.070 |
Why?
|
| Genotype | 3 | 2013 | 12863 | 0.060 |
Why?
|
| Genomic Instability | 1 | 2008 | 697 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 3490 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2009 | 1238 | 0.060 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 2459 | 0.060 |
Why?
|
| Apoptosis | 3 | 2018 | 10085 | 0.060 |
Why?
|
| Genome, Human | 1 | 2016 | 4493 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2709 | 0.060 |
Why?
|
| Epithelium | 3 | 2013 | 1740 | 0.060 |
Why?
|
| Signal Transduction | 7 | 2021 | 23950 | 0.060 |
Why?
|
| Robotics | 1 | 2010 | 859 | 0.060 |
Why?
|
| Calcitonin | 1 | 2004 | 352 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 3645 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2315 | 0.060 |
Why?
|
| Contrast Media | 4 | 2017 | 5267 | 0.060 |
Why?
|
| Mitochondria | 2 | 2016 | 3665 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 192 | 0.050 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 265 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3418 | 0.050 |
Why?
|
| Medical Errors | 1 | 2010 | 1300 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 2144 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2010 | 2563 | 0.050 |
Why?
|
| Specimen Handling | 2 | 2020 | 693 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2012 | 2587 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2016 | 916 | 0.050 |
Why?
|
| Neprilysin | 1 | 2003 | 425 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 7026 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2012 | 2048 | 0.050 |
Why?
|
| Keratins | 1 | 2021 | 534 | 0.050 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 48 | 0.050 |
Why?
|
| Granuloma | 1 | 2022 | 331 | 0.050 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 2307 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2022 | 464 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1894 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2274 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 408 | 0.040 |
Why?
|
| Adolescent | 8 | 2022 | 84718 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 2040 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 377 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2015 | 39292 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 664 | 0.040 |
Why?
|
| Omentum | 1 | 2019 | 157 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 1182 | 0.040 |
Why?
|
| Alleles | 3 | 2017 | 7090 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2015 | 1906 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 3714 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 582 | 0.040 |
Why?
|
| Online Systems | 1 | 2019 | 193 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39038 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 6571 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 3812 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9907 | 0.040 |
Why?
|
| Genomics | 3 | 2021 | 5300 | 0.040 |
Why?
|
| Transsexualism | 1 | 2020 | 152 | 0.040 |
Why?
|
| Necrosis | 1 | 2021 | 1646 | 0.040 |
Why?
|
| Mullerian Ducts | 1 | 2018 | 187 | 0.040 |
Why?
|
| Mice | 8 | 2017 | 80876 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2017 | 173 | 0.040 |
Why?
|
| Muscles | 1 | 2021 | 1622 | 0.040 |
Why?
|
| Cyclization | 1 | 2016 | 65 | 0.040 |
Why?
|
| Fibronectins | 1 | 2020 | 734 | 0.040 |
Why?
|
| Proportional Hazards Models | 4 | 2014 | 12292 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 2865 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2017 | 318 | 0.040 |
Why?
|
| Cell Survival | 2 | 2017 | 6156 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2022 | 4099 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 1158 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 4810 | 0.040 |
Why?
|
| Animals | 10 | 2017 | 170486 | 0.040 |
Why?
|
| Neoplasms | 2 | 2016 | 20172 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2014 | 2235 | 0.040 |
Why?
|
| Palliative Care | 1 | 2010 | 3261 | 0.030 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 281 | 0.030 |
Why?
|
| Endometriosis | 1 | 2003 | 773 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 1004 | 0.030 |
Why?
|
| World Health Organization | 1 | 2021 | 1261 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 258 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 317 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 358 | 0.030 |
Why?
|
| Pathology, Clinical | 1 | 2018 | 368 | 0.030 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 1210 | 0.030 |
Why?
|
| Morphogenesis | 1 | 2018 | 787 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 732 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 1276 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 135 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 681 | 0.030 |
Why?
|
| Brazil | 1 | 2018 | 1129 | 0.030 |
Why?
|
| Pregnancy | 1 | 2015 | 26832 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 4837 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 3515 | 0.030 |
Why?
|
| Data Mining | 1 | 2018 | 540 | 0.030 |
Why?
|
| Morpholines | 1 | 2016 | 572 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 1915 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 |